Dana-Farber Cancer Institute

308 articles about Dana-Farber Cancer Institute

• "CYCLOPS" Genes May Serve as an Achilles' Heel in Tumor Cells, Dana-Farber Cancer Institute and Broad Institute Study

  8/16/2012

• Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber Cancer Institute for Start of Clinical Trials

  8/6/2012

• Dana-Farber Cancer Institute Appoints Chief Operating Officer, Chief Financial Officer

  8/1/2012

• Newly Identified 'Beige Fat' Cells Could Help Fight Obesity, Dana-Farber Cancer Institute Study

  7/13/2012

• Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at Harvard's Dana-Farber Cancer Institute

  6/26/2012

• Publicity Club of New England Presents Dana-Farber Cancer Institute with $2,000 Check

  6/8/2012

• Antioxidant Beta-Carotene Use Safe During Radiation Treatment for Prostate Cancer, Dana-Farber Cancer Institute Study

  6/1/2012

• Marked for Destruction: Newly Developed Compound Triggers Cancer Cell Death, Dana-Farber Cancer Institute Study

  5/29/2012

• Mouse Study Sheds Light on How Diet May Affect Epilepsy, Dana-Farber Cancer Institute and Harvard Medical School Study

  5/24/2012

• Hormone-Depleting Drug Shows Promise Against Localized High-Risk Prostate Tumors, Dana-Farber Cancer Institute Study

  5/17/2012

• Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science to Present at American Association for Cancer Research Special Conference Molecular Targeted Therapies: Mechanisms of Resistance

  5/3/2012

• Target Set on Cancer Gene MCL1, Dana-Farber Cancer Institute Study

  4/17/2012

• Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science to Present and Lead Sessions at the American Association for Cancer Research Annual Meeting 2012

  3/26/2012

• Koch Institute, Dana-Farber Cancer Institute/ Harvard Cancer Center Announce Launch of “Bridge Project” to Attack Most Lethal Forms of Cancer

  3/6/2012

• Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science Appoints New Head of Research

  2/14/2012

• OncoPep Enters Exclusive License Agreement with Dana-Farber Cancer Institute for Novel Therapeutic Multi-Peptide Vaccine Technology for Hematologic Cancers

  2/13/2012

• Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer

  2/13/2012

• Massachusetts Life Sciences Center Grant Expands Dana-Farber Cancer Institute Imaging Research Program

  1/31/2012

• Ember Therapeutics Announces Nature Publication of Brown Fat Biology Data; Program Exclusively Licensed from the Dana-Farber Cancer Institute

  1/11/2012

• Dana-Farber Cancer Institute Researchers Identify Genetic Mutation Responsible for Most Cases of Waldenstrom's Macroglobulinemia

  12/16/2011